Sheet 1 of 3FORM PTO-1449  
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
480208.408D1APPLICATION NO.  
10/788,649INFORMATION DISCLOSURE STATEMENT  
(Use several sheets if necessary)

APPLICANTS

Thomas D. Madden et al.

FILING DATE

February 27, 2004

GROUP ART UNIT

1636

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
<i>lu</i>	AA	4,235,871	11/25/80	Papahadjopoulos et al.	424	19	
	AB	4,501,728	02/26/85	Geho et al.	424	38	
	AC	4,837,028	06/06/89	Allen	424	450	
	AD	5,023,087	06/11/91	Yau-Young	424	450	
	AE	5,552,156	09/03/96	Burke	424	450	
	AF	5,814,335	09/29/98	Webb et al.	424	450	
	AG	5,837,282	11/17/98	Fenske et al.	424	450	
	AH	5,976,567	11/02/99	Wheeler et al.	424	450	
	AI	6,110,491	08/29/00	Kirpotin	424	450	
<i>lu</i>	AJ	6,355,268	03/12/02	Slater et al.	424	450	

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
<i>lu</i>	AK	WO 95/08986	04/06/95	WIPO		
	AL	WO 98/17256	04/30/98	WIPO		
	AM	WO 99/51202	10/14/99	WIPO		
	AN	WO 00/23052	04/27/00	WIPO		
	AO	WO 99/13816	03/25/99	WIPO		

## OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>lu</i>	AP	Burris, H., et al., "Activity of Topotecan, a New Topoisomerase I Inhibitor, Against Human Tumor Colony-Forming Units In Vitro," <i>J. Natl. Cancer Inst.</i> 84(23):1816-1820, December 2, 1992.
<i>lu</i>	AQ	Clements, M., et al., "Antiangiogenic Potential of Camptothecin and Topotecan," <i>Cancer Chemother. Pharmacol.</i> 44:Pages 411-416, 1999.


EXAMINER

*ku*

DATE CONSIDERED

*12/04*

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480208.408D1		APPLICATION NO. 10/788,649	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Thomas D. Madden et al.			
				FILING DATE February 27, 2004		GROUP ART UNIT 1636	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
LM	BA	60/215,556	Madden et al.			06/30/00	
LM	BB	09/896,812	Madden et al.			06/29/01	
LM	BC	60/264,616	Madden et al.			01/26/01	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION	
						YES	NO
	BD						
<b>OTHER PRIOR ART</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
LM	BE	Corbett, T., et al., chapter 5 "In Vivo Methods for Screening and Preclinical Testing," in B. Teicher, Ed., <i>Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval</i> , Humana Press Inc., Totowa, NJ, 1997, pp.75-99.					
	BF	Emerson, D., et al., "In Vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues," <i>Cancer Res.</i> 55:603-609, February 1, 1995.					
	BG	Erickson-Miller, C., et al., "Differential Toxicity of Camptothecin, Topotecan and 9-Aminocamptothecin to Human, Canine, and Murine Myeloid Progenitors (CFU-GM) in Vitro," <i>Cancer Chemother. Pharmacol.</i> 39:467-472, 1997.					
	BH	Grochow, L., et al., "Pharmacokinetics and Pharmacodynamics of Topotecan in Patients with Advanced Cancer," <i>Drug Metab. Dispos.</i> 20(5):706-713, 1992.					
	BI	Hardman, W., et al., "Efficacy of Treatment of Colon, Lung and Breast Human Carcinoma Xenografts With: Doxorubicin, Cisplatin, Irinotecan or Topotecan," <i>Anticancer Res.</i> 19:2269-2274, 1999.					
	BJ	Hope, M., et al., "Generation of Multilamellar and Unilamellar Phospholipid Vesicles," <i>Chem. Phys. Lip.</i> 40:89-107, 1986.					
	BK	Hsiang, Y-H., et al., "Identification of Mammalian DNA Topoisomerase I as an Intracellular Target of the Anticancer Drug Camptothecin," <i>Cancer Res.</i> 48:1722-1726, April 1988.					
	BL	Kearney, A. et al., "Preformulation Studies to Aid in the Development of a Ready-to-Use Injectable Solution of the Antitumor Agent, Topotecan," <i>Int. J. Pharm.</i> 127:229-237, 1996.					
	BM	Gruner, S., chapter 1 "Materials Properties of Liposomal Bilayers," in Ostro, M.J. (ed.), <i>Liposomes: From Biophysics to Therapeutics</i> , Marcel Dekker, New York, 1993, pp. 1-38.					
LM	BN	Madden, T., et al. "The Accumulation of Drugs Within Large Unilamellar Vesicles Exhibiting a Proton Gradient: A Survey," <i>Chem. Phys. Lipids</i> 53:37-46, 1990.					
EXAMINER 				DATE CONSIDERED 12/04			
<p>* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).</p>							

FORM PTO-1449 (REV.7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 480208.408D1		APPLICATION NO. 10/788,649	
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)				APPLICANTS Thomas D. Madden et al.			
				FILING DATE February 27, 2004		GROUP ART UNIT 1636	
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION
							YES NO
	CB						
<b>OTHER PRIOR ART</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>							
lu	CC	Madden, T., et al., "Encapsulation of Topotecan in Lipid-based Carrier Systems. Evaluation of Drug Stability and Plasma Elimination in a Murine Model, and Comparison of Antitumor Efficacy Against Murine L1210 and B16 Tumors," <i>Proc. Of ASCO</i> 17, abstract #754, 1998.					
↑	CD	Mayer, L., et al., "Characterization of Liposomal Systems Containing Doxorubicin Entrapped in Response to pH Gradients," <i>Biochim. Biophys. Acta</i> 1025:143-151, 1990.					
	CE	McCabe, F., et al., "Comparative Activity of Oral and Parenteral Topotecan in Murine Tumor Models: Efficacy of Oral Topotecan," <i>Cancer Invest.</i> 12(3):308-313, 1994.					
	CF	O'Leary, J., et al., "Antiangiogenic Effects of Camptothecin Analogues 9-Amino-20 (S)-Camptothecin, Topotecan, and CPT-11 Studied in the Mouse Cornea Model," <i>Clin Cancer Res.</i> 5:181-187, January 1999.					
	CG	Ormrod, D. et al., "Topotecan A Review of its Efficacy in Small Cell Lung Cancer," <i>Drugs</i> 58(3):533-551, September 1999.					
	CH	Plowman, J., et al., chapter 6, "Human Tumor Xenograft Models in NCI Drug Development," in B. Teicher, Ed, <i>In Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval</i> , Humana Press Inc., Totowa, NJ, 1997.					
	CI	Szoka, F., et al., "Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes)," <i>Ann. Rev. Biophys. Bioeng.</i> 9:467- 508, 1980.					
	CJ	Tardi, P., et al., "Liposomal Encapsulation of Topotecan Enhances Anticancer Efficacy in Murine and Human Xenograft Models," <i>Cancer Res.</i> 60:3389-3393, July 2000.					
	CK	Thompson, J., et al., "Animal Models for Studying the Action of Topoisomerase I Targeted Drugs," <i>Biochim. Biophys. Acta</i> 1400:301-319, 1998.					
	CL	Wall, M., et al., "Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca Acuminata," <i>J. Am Chem. Soc.</i> 88:3888-3890, August 1966.					
lu	CM	Waud, W., chapter 4 "Murine L1210 and P388 Leukemias," In B. Teicher, Ed, <i>Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval</i> , Humana Press Inc., Totowa, NJ, 1997.					
EXAMINER				DATE CONSIDERED			
				12/04			
* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).							